2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: Synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling

Journal of Medicinal Chemistry

Volumn 41, Issue 19, 1998, Pages 3690-3698

  Koren, Andrei O ^a   Horti, Andrew G ^a   Mukhin, Alexey G ^a   Gündisch, Daniela ^a   Kimes, Alane S ^a   Dannals, Robert F ^b   London, Edythe D ^a  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 FLUORO 3 (AZETIDINYLMETHOXY)PYRIDINE F 18; CHOLINERGIC RECEPTOR; EPIBATIDINE; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG EFFECT; DRUG SCREENING; DRUG SYNTHESIS; MOLECULAR MODEL; RECEPTOR AFFINITY;

ANIMALS; AZETIDINES; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; LIGANDS; MALE; MODELS, MOLECULAR; NICOTINIC AGONISTS; PROSENCEPHALON; PYRIDINES; RATS; RATS, INBRED F344; RECEPTORS, NICOTINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032505152     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980170a     Document Type: Article

References (45)

1. Arneric, S. P.; Sullivan, J. P.; Williams, M. Neuronal Nicotinic Acetylcholine Receptors: Novel Targets for Central Nervous System Therapeutics. In Psychopharmacology: The Fourth Generation of Progress; Bloom, F. E., Kupfer, D. J., Eds.; Raven Press, Ltd.: New York, 1995; pp 95-110.
2. Bannon, A. W.; Decker, M. W.; Williams, M.; Arneric, S. P. Psychotherapeutic Potential of Selective Neuronal Nicotinic Acetylcholine Receptor Ligands. In Brain Imaging of Nicotine and Tobacco Smoking; Domino, E. F., Ed.; NPP Books: Ann Arbor, MI, 1995; pp 311-334.
3. Newhouse, P. A.; Potter, A.; Levin, E. D. Nicotinic System Involvement in Alzheimer's and Parkinson's Diseases. Implications for Therapeutics. Drugs Aging 1997, 11, 206-228.
4. Levin, E. D.; Conners, C. K.; Sparrow, E.; Hinton S. C.; Erhardt, D.; Meek, W. H.; Rose, J. E.; March J. Nicotine effects on adults with attention-deficit/hyperactivity disorder. Psychopharmacology 1996, 123, 55-63.
5. Sanberg, P. R.; Silver, A. A.; Shytle, R. D.; Philipp, M. K.; Cahill, D. W.; Fogelson, H. M.; McConville, B. J. Nicotine for the Treatment of Tourette's Syndrome. Pharmacol. Ther. 1997, 74, 21-25.
6. Salin-Pascual, R. J.; Rosas, M.; Jimenez-Genchi, A.; Rivera-Meza, B. L.; Delgado-Parra, V. Antidepressant Effect of Transdermal Nicotine Patches in Nonsmoking Patients with Major Depression. J. Clin. Psychiat. 1996, 57, 387-389.
7. 3H]Nicotine Binding in Human Postmortem Brain. J. Pharmacol. Exp. Ther. 1997, 282, 7-13.
8. 1C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis. Assoc. Disord. 1995, 9, 21-27.
9. 11C: Synthesis and Distribution Kinetics in Animals. Eur. J. Nucl. Med. 1976, 1, 255-258.
10. 1C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology 1994, 115, 31-36.
11. 18F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane. J. Labeled Compd. Radiopharm. 1996, 38, 355-365.
12. 18]Fluoroethylepibatidine: Ligands for the Neuronal Nicotinic Receptor. J. Labeled Compd. Radiopharm. 1995, 37, 355-356.
13. Musachio, J. L.; Horti, A.; London, E. D.; Dannals, R. F. Synthesis of a Radioiodinated Analogue of Epibatidine: (±)-exo-2-(2-iodo-5-pyridyl)-7-azabicyclo[2.2.1]heptane for in vitro and in vivo studies of nicotinic acetylcholine receptors. J. Labeled Compd. Radiopharm. 1997, 39, 39-48.
14. Saji, H.; Watanabe, A.; Magata, Y.; Ohmomo, Y.; Kiyono, Y.; Yamada, Y.; Iida, Y.; Yonekura, Y.; Konishi, J.; Yokoyama, A. Synthesis and Characterization of Radioiodinated (S)-5-Iodonicotine: A New Ligand for Potential Imaging of Brain Nicotinic Cholinergic Receptors by Single Photon Emission Computed Tomography. Chem. Pharm. Bull. 1997, 45, 284-290.
15. Abreo, M. A.; Lin, N.-H.; Garvey, D. S.; Gunn, D. E.; Hettinger, A.-M.; Wasicak, J. T.; Pavlik, P. A.; Martin, Y. C.; Donnelly-Roberts, D. L.; Anderson, D. J.; Suilivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Novel 3-Pyridyl Ethers with Subnanomolar Affinity for Central Neuronal Nicotinic Acetylcholine Receptors. J. Med. Chem. 1996, 39, 817-825.
16. Lin, N.-H.; Gunn, D. E.; Li, Y.; He, Y.; Bai, H.; Ryther, K. B.; Kuntzweiler, T.; Donnelly-Roberts, D. L.; Anderson. D. J.; Campbell, J. E.; Sullivan, J. P.; Arneric, S. P.; Holladay, M. W. Synthesis and Structure-Activity Relationships of Pyridine-Modified Analogues of 3-[2-((S)-Pyrrolidinyl)methoxy]pyridine, A-84543, a Potent Nicotinic Acetylcholine Receptor Agonist. Bioorg. Med. Chem. Lett. 1998, 8, 249-254.
17. Lin, N.-H.; Li, Y.; He, Y.; Donnelly-Roberts, D. L.; Anderson, D. J.; Campbell, J. E.; Arneric, S. P.; Holladay, M. W. Synthesis and Structure-Activity Relationships of 5-Substituted Pyridine Analogues of 3-[2-((S)-Pyrrolidinyl)methoxylpyridine, A-84543, a Potent Cholinergic Channel Modulator. Abstracts of Papers, 214th ACS National Meeting, 1997; MEDI008.
18. Holladay, M. W.; Lin, N.-H.; Ryther, K. B.; He, Y. 3-Pyridyloxyalkyl Heterocyclic Ether Compounds Useful in Controlling Chemical Synaptic Transmission. PCT International Publication WO 96/40682, Dec 19, 1996.
19. Lin, N.-H.; Gunn, D. E.; Ryther, K. B.; Garvey, D. S.; Donnelly-Roberts, D. L.; Decker, M. W.; Brioni, J. D.; Buckley, M. J.; Rodrigues, A. D.; Marsh, K. G.; Anderson, D. J.; Buccafusco, J. J.; Prendergast, M. A.; Sullivan, J. P.; Williams, M.; Arneric, S. P.; Holladay, M. W. Structure-Activity Studies on 2-Methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): An Orally Bioavailable 3-Pyridyl Ether Nicotinic Acetylcholine Receptor Ligand with Cognition-Enhancing Properties. J. Med. Chem. 1997, 40, 385-390.
20. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Xue, I. C.; Piattoni-Kaplan, M.; Molinari, E.; Campbell, J. E.; McKenna, D. G.; Gunn, D. E.; Lin, N.-H.; Ryther, K. B.; He, Y.; Holladay, M. W.; Wonnacott, S.; Williams, M.; Arneric, S. P. ABT-089 [2-Methyl-3(2-(S)-pyrrolidinylmethoxy)pyridine]: I. A Potent and Selective Cholinergic Channel Modulator with Neuroprotective Properties. J. Pharmacol. Exp. Ther. 1997, 283, 235-246.
21. Decker, M. W.; Bannon, A. W.; Curzon, P.; Gunther, K. L.; Brioni, J. D.; Holladay, M. W.; Lin, N.-H.; Li, Y.; Daanen, J. F.; Buccafusco, J. J.; Prendergast, M. A.; Jackson, W. J.; Arneric, S. P. ABT-089 [2-Methyl-3(2-(S)-Pyrrolidinylmethoxy)Pyridine Dihydrochloride]: II. A Novel Cholinergic Channel Modulator with Effects on Cognitive Performance in Rats and Monkeys. J. Pharmacol. Exp. Ther. 1997, 283, 247-258.
22. 11C]Methyl-2(R)-pyrrolidinyl)methoxy]pyridine: Radioligands for In Vivo Studies of Neuronal Nicotinic Acetylcholine Receptors. J. Labeled Compd. Radiopharm. 1997, 39, 425-431.
23. Kassiou, M.; Scheffel, U. A.; Ravert, H. T.; Mathews, W. B.; Musachio, J. L.; London, E. D.; Dannals, R. F. C-11 A-84543: An Enantioselective Ligand for In Vivo Studies of Neuronal Nicotinic Acetylcholine Receptors. J. Nucl. Med. 1997, 38, 65P.
24. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Piattoni-Kaplan, M.; Campbell, J. E.; McKenna, D. G.; Molinari, E.; Hettinger, A.-M.; Garvey, D. S.; Wasicak, J. T.; Holladay, M. W.; Williams, M.; Arneric, S. P. A-85380 [3-(2(S)-Azetidinylmethoxy) Pyridine]: In Vitro Pharmacological Properties of a Novel, High Affinity α4/β2 Nicotinic Acetylcholine Receptor Ligand. Neuropharmacology 1996, 35, 725-734.
25. 3H]-Cytisine Binding in Rat and Mouse Brain. Soc. Neurosci. Abstr. 1996, 22, 1264.
26. Holladay, M. W.; Wasicak, J. T.; Lin, N.-H.; He, Y.; Ryther, K. B.; Bannon, A. W.; Buckley, M. J.; Kim, D. J. B.; Decker, M. W.; Anderson, D. J.; Campbell, J. E.; Kuntzweiler, T. A.; Donnelly-Roberts, D. L.; Piattoni-Kaplan, M.; Briggs, C. A.; Williams, M.; Arneric, S. P. Identification and Initial Structure-Activity Relationships of (R)-5-(2-Azetidinylmethoxy)-2-chloropyridine (ABT-594), a Potent, Orally Active, Non-Opiate Analgesic Agent Acting via Neuronal Nicotinic Acetylcholine Receptors. J. Med. Chem. 1998, 41, 407-412.
27. Barnes, R. A. Properties and Reactions of Pyridine and Its Hydrogenated Derivatives. In Pyridine and Its Derivatives; Klingsberg, E., Ed.; Interscience Publishers: New York, 1960; pp 1-97.
28. Sheldrake, P. W.; Powling, L. C.; Slaich, P. K. Preparation of 5-Hydroxy-2-iodopyridine: A Refutation of Earlier Reports. J. Org. Chem. 1997, 62, 3008-3009.
29. Heindl, J.; Kelm, H.-W.; Dogs, E.; Seeger, A.; Herrmann, C. Untersuchungen über die antibakterielle Aktivität von Chinoloncarbonsäuren. IX. Azaanaloga. Di- und trisubstituierte 1,4-Dihydro-4-oxo-1,5-naphthyridin-3-carbonsäuren und 1-Äthyl-4-pyridon-3-carbonsäure. (Studies of antibacterial activity of quinolonecarboxylic acids. IX. Azaanalogs. Di- and trisubstituted 1,4-Dihydro-4-oxo-1,5-naphthyridine-3-carboxylic acids and 1-ethyl-4-pyridone-3-carboxylic acid.) Eur. J. Med. Chem. 1977, 12, 549-555.
30. Fukuhara, T.; Yoneda, N.; Suzuki, A. A Facile Preparation of Fluoropyridines from Aminopyridines via Diazotization and Fluorodediazonization in HF or HF-Pyridine Solutions. J. Fluorine Chem. 1988, 38, 435-438.
31. Yamamoto, Y.; Yanagi, A. Studies on Organometallic Compounds. II. Facile and Convenient Method for the Synthesis of Iodoazines through Iododestannation of Trimethylstannylazines. Chem. Pharm. Bull. 1982, 30, 1731-1737.
32. Vowinkel, E. Darstellung von Arylalkyläthern mittels O-Alkyl-N,N′-dicyclohexyl-isoharnstoffen. (Synthesis of aryl alkyl ethers using O-alkyl-N,N′-dicyclohexylureas.) Chem. Ber. 1966, 99, 1479-1484.
33. 3H]Epibatidine Binding to Nicotinic Cholinergic Receptors in Rat and Human Brain. Mol. Pharmacol. 1995, 48, 280-287.
34. Flores, C. M.; Rogers, S. W.; Pabreza, L. A.; Wolfe, B. B.; Kellar, K. J. A Subtype of Nicotinic Cholinergic Receptor in Rat Brain Is Composed of α4 and β2 Subunits and Is Up-regulated by Chronic Nicotine Treatment. Mol. Pharmacol. 1992, 41, 31-37.
35. Sheridan, R. P.; Nilakantan, R.; Dixon, J. S.; Venkataraghavan, R. The Ensemble Approach to Distance Geometry: Application to the Nicotinic Pharmacophore. J. Med. Chem. 1986, 29, 899-906.
36. Dukat, M.; Damaj, M. I.; Glassco, W.; Dumas, D.; May, E. L.; Martin, B. R.; Glennon, R. A. Epibatidine: A Very High Affinity Nicotine-Receptor Ligand. Med. Chem. Res. 1994, 4, 131-139.
37. Glennon, R. A.; Herndon, J. L.; Dukat, M. Epibatidine-Aided Studies Toward Definition of a Nicotine Receptor Pharmacophore. Med. Chem. Res. 1994, 4, 461-473.
38. Dewar, M. J. S.; Zoebisch, E. G.; Healy, E. F.; Stewart, J. J. P. AM1: A New General Purpose Quantum Mechanical Molecular Model. J. Am. Chem. Soc. 1985, 107, 3902-3909.
39. Glennon, R. A.; Dukat, M. Nicotine Receptor Ligands. Med. Chem. Res. 1996, 6, 465-486.
40. Ziegler, F. E.; Bennett, G. B. The Claisen Rearrangement in Indole Alkaloid Synthesis. The Total Synthesis of (±)-Tabersonine. J. Am. Chem. Soc. 1973, 95, 7458-7464.
41. Mukhin, A.; Kovaleva, E. S.; London, E. D. Two Affinity States of N-Methyl-D-Aspartate Recognition Sites: Modulation by Cations. J. Pharmacol. Exp. Ther. 1997, 282, 945-954.
42. Bradford, M. M. A Rapid and Sensitive Method for The Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding. Anal. Biochem. 1976, 72, 248-254.
43. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
44. Quantum Chemistry Program Exchange, Creative Arts Bldg 181, Indiana University, Bloomington, IN 47405.
45. CambridgeSoft Corp., 875 Massachusetts Ave., Cambridge, MA 02139.